Results 31 to 40 of about 8,865 (194)
Slow synaptic transmission in frog sympathetic ganglia [PDF]
, 1986 Bullfrog ganglia contain two classes of neurone, B and C cells, which receive different inputs and exhibit different slow synaptic potentials. B cells, to which most effort has been directed, possess slow and late slow EPSPs.
Adams, P. R. +5 more
core +2 more sources
Differential Gene Expression in Gonadotropin-Releasing Hormone Neurons of Male and Metestrous Female Mice. [PDF]
, 2015 BACKGROUND: Gonadotropin-releasing hormone (GnRH) neurons play a pivotal role in regulation of the hypothalamic-pituitary gonadal axis in a sex-specific manner.
Auer, H. +6 more
core +1 more source
The Prostate, Volume 86, Issue 8, Page 961-969, June 2026.ABSTRACT Background Unfavorable intermediate‐risk prostate cancer (UIR‐PCa) represents a biologically heterogeneous subgroup with a higher risk of recurrence compared with favorable intermediate‐risk disease. Contemporary management frequently includes dose‐escalated radiotherapy (RT) combined with short‐term androgen deprivation therapy (ADT). Whether
Cem Onal +5 more
wiley +1 more source
Effekte des LHRH-Agonisten Triptorelin auf die in vitro Proliferation verschiedener Ovarial- und Endometriumkarzinomzellinien [PDF]
, 2005 5. Zusammenfassung Ovarial- und Endometriumkarzinome sind in den weiter fortgeschrittenen, rezidivierten oder gar metastasierten Stadien schwierig zu behandeln.
Emons, Günter (Prof. Dr.) +1 more
core +1 more source
Castration Resistance Accelerates Prostate Cancer Kinetics
The Prostate, Volume 86, Issue 9, Page 1021-1027, June 15, 2026.ABSTRACT Background Prostate cancer can be an indolent disease with which patients can live for many years. Thus, an understanding of how therapy and its ensuing resistance affect prostate cancer kinetics may guide efforts to determine optimal timing of therapy initiation.
Sheila Jonnatan +10 more
wiley +1 more source
New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones [PDF]
, 2015 It is a pleasure to contribute our presentation at the International Prostate Forum of the Annual Meeting of the American Urological Association (AUA) to this special issue of the Asian Journal of ...
Block, Norman L. +2 more
core +3 more sources
Exploring Lived Experiences of Men Diagnosed With Prostate Cancer in Oman: A Qualitative Study
Health Expectations, Volume 29, Issue 3, June 2026.ABSTRACT Background Life after prostate cancer treatment may extend across decades; however, qualitative evidence describing how men in Oman navigate treatment sequelae, disclosure, family involvement, and religious coping remains limited. This study explored the lived experiences of Omani men who had completed primary therapy for prostate cancer ...
Khalood Al‐Abri +6 more
wiley +1 more source
Antisense-Expression des Gens für den Rezeptor des humanen Lutein-Hormon-Releasing-Hormon (LHRH) in der humanen Ovarialkarzinomzelllinie EFO 21 mittels des Ecdysone-Systems [PDF]
, 2004 Das Ovarialkarzinom hat aufgrund fehlender Früherkennung immer noch eine sehr schlechte Prognose, so dass in der Therapie weitere Fortschritte benötigt werden.
Backhus, Jan Hendrik +1 more
core +1 more source
The Prostate, Volume 86, Issue 6, Page 697-709, May 2026.ABSTRACT Background Combined inhibition of AKT and the androgen receptor (AR) might be more efficacious than AR inhibition alone in biochemical recurrence (BCR) of prostate cancer (PC) by additive effects on the two effector pathways. Patients and Methods E2809 assigned 108 high‐risk BCR patients (1:1, arm‐A: arm‐B) to two phases with 4‐week cycles ...
Anna C. Ferrari +12 more
wiley +1 more source
Hormonal therapy for cancer [PDF]
, 2016 Hormone therapy is an effective and non-toxic therapy for oestrogen and progesterone receptor-positive breast cancer and prostate cancer. Serum levels of oestradiol and testosterone are controlled by the hypothalamic–pituitary–gonadal pathway. Oestradiol
Abraham, Jacinta +1 more
core +2 more sources